ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,555.80
0.19%
S&P ASX All Technology
4,107.60
0.90%
Brent Oil
74.39
0.00%
US Dollar vs AUD
1.57356
-0.07%
Bitcoin
97,604.25
0.08%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) News

ZYME

Zymeworks (ZYME)

Zymeworks Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZYME
DateTimeSourceHeadlineSymbolCompany
13/02/202522:00GlobeNewswire Inc.Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025NASDAQ:ZYMEZymeworks Inc
30/01/202522:00GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
14/01/202511:18Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ZYMEZymeworks Inc
11/01/202510:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
09/01/202508:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
09/01/202508:05GlobeNewswire Inc.Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026NASDAQ:ZYMEZymeworks Inc
07/01/202512:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
07/01/202511:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZYMEZymeworks Inc
13/12/202410:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
13/12/202409:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
13/12/202409:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZYMEZymeworks Inc
13/12/202400:30GlobeNewswire Inc.Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory DiseasesNASDAQ:ZYMEZymeworks Inc
12/12/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
22/11/202408:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
21/11/202422:05GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
21/11/202422:00GlobeNewswire Inc.FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)NASDAQ:ZYMEZymeworks Inc
05/11/202422:00GlobeNewswire Inc.Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid TumorsNASDAQ:ZYMEZymeworks Inc
01/11/202407:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZYMEZymeworks Inc
01/11/202407:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
01/11/202407:05GlobeNewswire Inc.Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:ZYMEZymeworks Inc
30/10/202407:11Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZYMEZymeworks Inc
30/10/202407:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZYMEZymeworks Inc
30/10/202407:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZYMEZymeworks Inc
29/10/202421:00GlobeNewswire Inc.Zymeworks Announces Participation in Upcoming Investor ConferencesNASDAQ:ZYMEZymeworks Inc
25/10/202421:00GlobeNewswire Inc.Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceNASDAQ:ZYMEZymeworks Inc
21/10/202421:00GlobeNewswire Inc.Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing CancersNASDAQ:ZYMEZymeworks Inc
19/10/202407:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZYMEZymeworks Inc
10/10/202421:30GlobeNewswire Inc.Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024NASDAQ:ZYMEZymeworks Inc
18/09/202420:00GlobeNewswire Inc.Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceNASDAQ:ZYMEZymeworks Inc
04/09/202406:30GlobeNewswire Inc.Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)NASDAQ:ZYMEZymeworks Inc
 Showing the most relevant articles for your search:NASDAQ:ZYME

Your Recent History

BIT
F17095
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads